You are here:Home Home>>Product Pipeline>MCV4


Meningococcal Conjugate ACW135Y Vaccine

Meningococcal meningitis is a life-threatening acute respiratory disease caused by Neisseria meningitidis (meningococcus). As a widespread invasive infection, it is associated with high mortality and drug resistance due to high mutation frequency of meningococca. About 90% of all meningococcal infections are caused by serotypes A, C, W135 and Y of this organism. Infants of 3-12 months old are most susceptible to meningitis. In 2010, a 4-valent meningitis conjugate vaccine (MCV-4), Menveo, was licensed by Novartis, which has been proved to be highly effective in young children above three months old. 

However, MCV-4 are still absent in Chinese market. In an effort to fill in this gap, CanSino has been striving to develop MCV-4 of better immunogenicity and safety via developing novel carriers and higher conjugation efficiency.